Dan Burns , President & Chief Executive Officer. Mr. Burns joined InfaCare Pharmaceutical as President and Chief Executive Officer in April 2007, bringing to the company more than 20 years of management experience in the pharmaceutical and biotechnology industries. Prior to joining InfaCare, from 2002 to 2007 Mr. Burns was a Corporate Officer at MannKind Corporation and held the positions of CEO PDC, President Commercial Operations, and President MannKind BioPharmaceuticals. He led the building of the Technosphere Technology Platform enabling the company to successfully complete a public offering in 2004. Mr. Burns served as Chief Executive Officer of HealthTalk Interactive, a pharmaceutical services firm, from 2000 to 2002. From 1998 to 1999 Mr. Burns served as Chief Executive Officer of ProScript, a biopharmaceutical company when the company filed an IND for Velcade and proceeded to the clinic. He subsequently negotiated the sale of ProScript to a public biopharmaceutical company. Mr. Burns served as President and Chief Operating Officer of Trophix Pharmaceuticals Inc. from 1997 to 1998 where he successfully merged Trophix with the largest public biopharmaceutical company in Canada. Prior to joining Trophix Mr. Burns held a number of senior executive positions both internationally and domestically with Bristol Myers Squibb.
Ronald Dundore, PhD., Vice President, Regulatory and Quality Affairs. Dr. Dundore is responsible for InfaCare’s regulatory, quality, and manufacturing operations. Previously he was Director, US Regulatory Affairs for AstraZeneca. and has over 20 years of experience in the pharmaceutical industry as a regulatory professional and as a research and development scientist. He served in a variety of regulatory roles at Rhone-Poulenc Rorer and Zeneca Pharmaceuticals. Prior to these assignments, Ron served as a toxicologist for the FDA and was responsible for the review of a number of NDA’s and IND’s. Dr. Dundore received his PhD in Pharmacology from Pennsylvania State University.